Modulation of miR-192/NF-κB/ TGF-β/ E-cadherin by thymoquinone protects against diethylnitrosamine /carbon tetrachloride hepatotoxicity

被引:3
|
作者
Ashour, Hend [1 ,2 ]
Farghaly, Maha Eid [3 ]
Khowailed, Akef Abdelhalim [2 ]
Aboulhoda, Basma Emad [4 ]
Rashed, Laila Ahmed [5 ]
Elsebaie, Mohamed Mahmoud [5 ]
Gaber, Safy Salah [3 ]
机构
[1] King Khalid Univ, Dept Med Physiol, Fac Med, Abha, Saudi Arabia
[2] Cairo Univ, Dept Med Physiol, Fac Med, Cairo, Egypt
[3] Beni Suef Univ, Dept Med Physiol, Fac Med, Bani Suwayf, Egypt
[4] Cairo Univ, Dept Anat & Embryol, Fac Med, Cairo, Egypt
[5] Cairo Univ, Dept Biochem, Fac Med, Cairo, Egypt
关键词
hepatocellular carcinoma; thymoquinone; microRNA-192; NF-kappa B; TGF-beta; E-cadherin; HEPATOCELLULAR-CARCINOMA; BREAST-CANCER; CELL APOPTOSIS; MIR-192; PATHWAY; GROWTH; MICROENVIRONMENT; CARCINOGENESIS; DYSREGULATION; INFLAMMATION;
D O I
10.1556/2060.2022.00163
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Scientific efforts have been made for a better understanding of the pathogenesis of hepatocellular carcinoma (HCC). We investigated the possible role of miR-192/nuclear factor-kappa B (NF-kappa B)/transforming growth factor-beta (TGF-beta)/E-cadherin in hepatic tumorigenesis. We expected a modulatory impact of thymoquinone. Thirty adult male rats were assigned into 3 groups (n = 10); (1) Control group. Group (2): Experimental HCC induced by intraperitoneal injection of diethylnitrosamine (DENA) followed by carbon tetrachloride (CCl4). Group (3): Thymoquinone 20 mg kg(-1)/oral supplementation starting from the model induction to the end of the 8th week. The HCC (DENA-CCL4) model was confirmed by elevated serum levels of alpha-fetoprotein and transaminases (ALT, AST) and by histopathological examination which denoted marked cellular atypia and features of neoplasia. Suppressed hepatic miR-192 and E-cadherin expression were detected in the HCC (DENA-CCL4) group accompanied by elevated tumor necrosis factor (TNF-alpha), interleukin (IL6)/NF-kappa B & TGF-beta 1. Thymoquinone treatment protected the rat livers from hepatic tumorigenesis. Thymoquinone diminished (P < 0.001) alpha-fetoprotein and improved ALT, AST. It preserved hepatic miR-192 and normal E-cadherin expression. Thymoquinone-treated rats showed abrogated TNF-alpha, IL6/NF-kappa B/TGF-beta. Thymoquinone increased cell apoptosis markers Bax/Bcl2 and diminished cellular atypia. Pearson's correlations revealed positive association between miR-192 expression and E-cadherin and Bax/Bcl2 as well, and it was negatively correlated to alpha-fetoprotein, NF-kappa B and TGF-beta and the cellular atypia score. In conclusion, thymoquinone protected the liver tissues through preserving miR-192 and E-cadherin and aborting NF-kappa B & TGF-beta signaling. The current results highlight a new role for thymoquinone in preventing hepatic tumorigenesis.
引用
收藏
页码:371 / 387
页数:17
相关论文
共 28 条
  • [21] Corosolic acid ameliorates non-alcoholic steatohepatitis induced by high-fat diet and carbon tetrachloride by regulating TGF-β1/Smad2, NF-κB, and AMPK signaling pathways
    Liu, Guancheng
    Cui, Zhe
    Gao, Xiaoyan
    Liu, Huizhe
    Wang, Linghe
    Gong, Jinyan
    Wang, Ao
    Zhang, Jianxiu
    Ma, Qianqian
    Huang, Yuan
    Piao, Guangchun
    Yuan, Haidan
    PHYTOTHERAPY RESEARCH, 2021, 35 (09) : 5214 - 5226
  • [22] Garcinone E Mitigates Oxidative Inflammatory Response and Protects against Experimental Autoimmune Hepatitis via Modulation of Nrf2/HO-1, NF-κB and TNF-α/JNK Axis
    Mohamed, Gamal A. A.
    Ibrahim, Sabrin R. M.
    Hareeri, Rawan H. H.
    Binmahfouz, Lenah S. S.
    Bagher, Amina M. M.
    Abdallah, Hossam M. M.
    Elsaed, Wael M. M.
    El-Agamy, Dina S. S.
    NUTRIENTS, 2023, 15 (01)
  • [23] Mechanistic insight into the hepatoprotective effect of Moringa oleifera Lam leaf extract and telmisartan against carbon tetrachloride-induced liver fibrosis: plausible roles of TGF-β1/SMAD3/SMAD7 and HDAC2/NF-κB/PPARγ pathways
    Baky, Nayira A. Abdel
    Fouad, Lamiaa M.
    Ahmed, Kawkab A.
    Alzokaky, Amany A.
    DRUG AND CHEMICAL TOXICOLOGY, 2025, 48 (01) : 84 - 97
  • [24] Retraction Note: Xia-yu-xue decoction (XYXD) reduces carbon tetrachloride (CCl4)-induced liver fibrosis through inhibition hepatic stellate cell activation by targeting NF-κB and TGF-β1 signaling pathways
    Cheng Liu
    Xia Yuan
    Le Tao
    Zhuoan Cheng
    Xiuqin Dai
    Xia Sheng
    Dongying Xue
    BMC Complementary Medicine and Therapies, 22
  • [25] RETRACTED ARTICLE: Xia-yu-xue decoction (XYXD) reduces carbon tetrachloride (CCl4)-induced liver fibrosis through inhibition hepatic stellate cell activation by targeting NF-κB and TGF-β1 signaling pathways
    Cheng Liu
    Xia Yuan
    Le Tao
    Zhuoan Cheng
    Xiuqin Dai
    Xia Sheng
    Dongying Xue
    BMC Complementary Medicine and Therapies, 15
  • [26] RETRACTED: Xia-yu-xue decoction (XYXD) reduces carbon tetrachloride (CCl4)-induced liver fibrosis through inhibition hepatic stellate cell activation by targeting NF-κB and TGF-β1 signaling pathways (Retracted Article)
    Liu, Cheng
    Yuan, Xia
    Tao, Le
    Cheng, Zhuoan
    Dai, Xiuqin
    Sheng, Xia
    Xue, Dongying
    BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2015, 15
  • [27] RETRACTION: Xia-yu-xue decoction (XYXD) reduces carbon tetrachloride (CCl4)-induced liver fibrosis through inhibition hepatic stellate cell activation by targeting NF-κB and TGF-β1 signaling pathways (Retraction of Vol 15, art no 201, 2015)
    Liu, Cheng
    Yuan, Xia
    Tao, Le
    Cheng, Zhuoan
    Dai, Xiuqin
    Sheng, Xia
    Xue, Dongying
    BMC COMPLEMENTARY MEDICINE AND THERAPIES, 2022, 22 (01)
  • [28] Correlation among 16 biological factors [p53, p21waf1, MIB-1 (Ki-67), p16INK4A, cyclin D1, E-cadherin, Bcl-2, TNF-α, NF-κB, TGF-β, MMP-7, COX-2, EGFR, HER2/neu, ER, and HIF-1α] and clinical outcomes following curative chemoradiation therapy in 10 patients with esophageal squamous cell carcinoma
    Shibata-Kobayashi, Shino
    Yamashita, Hideomi
    Okuma, Kae
    Shiraishi, Kenshiro
    Igaki, Hiroshi
    Ohtomo, Kuni
    Nakagawa, Keiichi
    ONCOLOGY LETTERS, 2013, 5 (03) : 903 - 910